The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?
Open Access
- 19 November 2020
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 10 (4), 237
- https://doi.org/10.3390/jpm10040237
Abstract
In recent decades, survival rates in colorectal cancer have improved greatly due to pharmacological treatment. However, many patients end up developing adverse drug reactions that can be severe or even life threatening, and that affect their quality of life. These remain a limitation, as they may force dose reduction or treatment discontinuation, diminishing treatment efficacy. From candidate gene approaches to genome-wide analysis, pharmacogenomic knowledge has advanced greatly, yet there is still huge and unexploited potential in the use of novel technologies such as next-generation sequencing strategies. This review summarises the road of colorectal cancer pharmacogenomics so far, presents considerations and directions to be taken for further works and discusses the path towards implementation into clinical practice.This publication has 165 references indexed in Scilit:
- A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimenThe Pharmacogenomics Journal, 2012
- A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancerBritish Journal of Cancer, 2011
- PharmGKB summaryPharmacogenetics and Genomics, 2011
- Towards a complete resolution of the genetic architecture of diseaseTrends in Genetics, 2010
- Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancerEuropean Journal of Cancer, 2010
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05Journal of Clinical Oncology, 2010
- Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancerThe Pharmacogenomics Journal, 2010
- Finding the missing heritability of complex diseasesNature, 2009
- Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancerBritish Journal of Cancer, 2009
- Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancerCancer, 2009